PL2504332T3 - Amorficzna i krystaliczna forma hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej - Google Patents
Amorficzna i krystaliczna forma hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowejInfo
- Publication number
- PL2504332T3 PL2504332T3 PL10785289T PL10785289T PL2504332T3 PL 2504332 T3 PL2504332 T3 PL 2504332T3 PL 10785289 T PL10785289 T PL 10785289T PL 10785289 T PL10785289 T PL 10785289T PL 2504332 T3 PL2504332 T3 PL 2504332T3
- Authority
- PL
- Poland
- Prior art keywords
- genz
- hemitartrate
- amorphous
- inhibitor
- crystalline form
- Prior art date
Links
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 title 1
- 108091000114 ceramide glucosyltransferase Proteins 0.000 title 1
- 229960002856 eliglustat Drugs 0.000 title 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 | |
| PCT/US2010/057952 WO2011066352A1 (en) | 2009-11-27 | 2010-11-24 | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
| EP10785289.9A EP2504332B2 (en) | 2009-11-27 | 2010-11-24 | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL2504332T3 true PL2504332T3 (pl) | 2014-10-31 |
| PL2504332T5 PL2504332T5 (pl) | 2021-08-23 |
Family
ID=43431870
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16175117T PL3133070T3 (pl) | 2009-11-27 | 2010-11-24 | Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta |
| PL10785289T PL2504332T5 (pl) | 2009-11-27 | 2010-11-24 | Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej |
| PL19182732T PL3599237T3 (pl) | 2009-11-27 | 2010-11-24 | Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta |
| PL14164650T PL2796457T3 (pl) | 2009-11-27 | 2010-11-24 | Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16175117T PL3133070T3 (pl) | 2009-11-27 | 2010-11-24 | Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19182732T PL3599237T3 (pl) | 2009-11-27 | 2010-11-24 | Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta |
| PL14164650T PL2796457T3 (pl) | 2009-11-27 | 2010-11-24 | Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego |
Country Status (41)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| PT3133070T (pt) | 2009-11-27 | 2019-11-11 | Genzyme Corp | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
| ES2664844T3 (es) * | 2011-06-20 | 2018-04-23 | Mount Sinai School Of Medicine | Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos |
| US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| PT2854910T (pt) | 2012-06-01 | 2020-05-06 | Yeda Res & Dev | Níveis de ceramida no tratamento e prevenção de infeções |
| ES2739811T3 (es) | 2013-03-14 | 2020-02-04 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas |
| EP3046920B1 (en) * | 2013-09-20 | 2021-08-04 | BioMarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| WO2016001885A2 (en) * | 2014-07-03 | 2016-01-07 | Dr. Reddy’S Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| ES2716420T3 (es) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Clorhidrato de eliglustat cristalino |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| EA201891170A1 (ru) | 2015-11-18 | 2018-11-30 | Джензим Корпорейшн | Биомаркер поликистозной болезни почек и варианты его применения |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) * | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| WO2018225085A1 (en) | 2017-06-05 | 2018-12-13 | Cipla Limited | Stable solid dispersions of eliglustat hemitartrate |
| CN110799191B (zh) * | 2017-06-16 | 2023-05-26 | 贝塔制药有限公司 | N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂 |
| US20200222310A1 (en) * | 2017-08-08 | 2020-07-16 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
| WO2019030645A1 (en) * | 2017-08-08 | 2019-02-14 | Kashiv Pharma Llc | Pharmaceutical composition comprising eliglustat |
| SG11202004954YA (en) | 2017-12-15 | 2020-06-29 | Genzyme Corp | Methods for treating gaucher disease |
| WO2019123476A1 (en) * | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| WO2019211778A2 (en) * | 2018-05-02 | 2019-11-07 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| WO2019231725A2 (en) * | 2018-05-27 | 2019-12-05 | Bioasis Technolgies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| HUT73527A (en) | 1993-08-13 | 1996-08-28 | Seikagaku Kogyo Co Ltd | Remedy for nervous diseases |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| DK0742789T3 (da) | 1994-02-02 | 2000-11-13 | Liposome Co Inc | Farmaceutisk aktive forbindelser og liposomer og fremgangsmåder til anvendelse af disse |
| AU698833B2 (en) | 1994-06-10 | 1998-11-12 | Seikagaku Corporation | 2-acylaminopropanol compound and medical composition |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| ATE358473T1 (de) | 1998-07-27 | 2007-04-15 | Univ Johns Hopkins | Diamino-propanol-verbindungen zur behandlung von ischaemien |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| AU774960B2 (en) * | 1999-07-09 | 2004-07-15 | Regents Of The University Of Michigan, The | Amino ceramide-like compounds and therapeutic methods of use |
| US20040252299A9 (en) | 2000-01-07 | 2004-12-16 | Lemmo Anthony V. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| CZ20023775A3 (cs) | 2000-04-24 | 2003-10-15 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrát |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2002062777A2 (en) | 2001-01-10 | 2002-08-15 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040043457A1 (en) * | 2001-01-18 | 2004-03-04 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
| DK2266968T3 (da) | 2001-07-16 | 2013-04-08 | Genzyme Corp | Syntese af UDP-glucose: N-acylsphingosin-glucosyltransferase-hæmmere |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| CA2459172C (en) | 2001-08-08 | 2011-07-05 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| AU2003251829B2 (en) | 2002-07-09 | 2009-12-10 | Radical Therapeutix | Method to inhibit ischemia and reperfusion injury |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| DE602005027308D1 (de) * | 2004-01-27 | 2011-05-19 | Synthon Bv | Stabile salze von olanzapin |
| EP2479290B1 (en) | 2004-09-30 | 2020-08-19 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| BRPI0516001A (pt) | 2004-10-13 | 2008-08-19 | Pharmacia & Upjohn Co Llc | formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida |
| EP1811991B1 (en) * | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| US20070088082A1 (en) * | 2005-09-28 | 2007-04-19 | Judith Aronhime | Polymorphic forms of ladostigil tartrate |
| JP2009510163A (ja) * | 2005-10-03 | 2009-03-12 | マリンクロッド・インコーポレイテッド | ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法 |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| EP2923699B1 (en) | 2006-05-09 | 2018-06-20 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| US20100113517A1 (en) * | 2007-03-30 | 2010-05-06 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| JP2010525084A (ja) * | 2007-04-26 | 2010-07-22 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画 |
| EP2594562B1 (en) * | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| US20090307180A1 (en) | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| SI2733142T1 (sl) | 2009-11-27 | 2018-10-30 | Adverio Pharma Gmbh | Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3il) pirimidin-5-il)metilkarbamata za uporabo kot farmacevtska učinkovina |
| PT3133070T (pt) | 2009-11-27 | 2019-11-11 | Genzyme Corp | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
| WO2012175522A1 (en) | 2011-06-21 | 2012-12-27 | Novartis Ag | Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en active Application Filing
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active IP Right Cessation
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active IP Right Grant
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en active Active
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Application Discontinuation
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko active Search and Examination
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active IP Right Cessation
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
- 2012-12-14 HK HK15103822.1A patent/HK1203485A1/zh unknown
- 2012-12-14 HK HK12112977.8A patent/HK1172031A1/xx unknown
-
2014
- 2014-08-18 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
- 2015-11-02 PH PH12015502514A patent/PH12015502514A1/en unknown
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en active Pending
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es unknown
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es unknown
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US20230172903A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283935A (en) | Crystalline and amorphous form of genz 112638 hemitartrate as an inhibitor of glucosylceramide synthase | |
| HK1254977A1 (zh) | 索非布韋(sofosbuvir)的結晶形式 | |
| HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
| HRP20170214T1 (hr) | Amorfna sol makrocikličkog inhibitora hcv | |
| IL210322A0 (en) | Crystalline salts of sitagliptin | |
| EP2421867A4 (en) | PANELID INHIBITORS OF JANUS KINASE 3 | |
| SI2155200T1 (sl) | Kristalinična oblika kabamoil-cikloheksanskega derivata | |
| PT2611779T (pt) | Formas cristalinas de um inibidor do fator xa | |
| IL221198A0 (en) | Crystalline salts of a potent hcv inhibitor | |
| HK1169408A1 (en) | Cdk inhibitor salts cdk | |
| SI2358676T1 (sl) | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine | |
| PL2439202T3 (pl) | Inhibitory dehydrogenazy 11b-hydroksysteroidowej typu 1 | |
| ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| HK1175780A1 (en) | Crystalline cdc7 inhibitor salts cdc7 | |
| HK1177459A1 (zh) | 因子抑制劑的結晶鹽 | |
| AP2717A (en) | Mono-hydrochloric salts of an inhibitor of histonedeacetylase | |
| HUP0800755A2 (en) | Crystalline forms of rosiglitazone | |
| EP2488530A4 (en) | INHIBITORS OF THE RENIN | |
| EP2482821A4 (en) | CRYSTALLINE HYDROCHLORIDE SALTS FROM C-MET KINASE INHIBITORS |